Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.38 |
| ▸ | BCL2A1 | Q16548 | 3/20 | 0.37 |
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | HTR2C | P28335 | 2/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3054040 | 0.90 | DGAT1 (0.38) | DPP4HTR2AHTR2CDGAT1HTR2B | |
| SCHEMBL3050243 | 0.87 | DPP4 (0.39) | DPP4DGAT1MAPTSMN1; SMN2 | |
| SCHEMBL3055541 | 0.83 | ALDH1A1 (0.41) | DPP4DGAT1 | |
| SCHEMBL3713246 | 0.83 | C5AR1 (0.39) | DPP4DGAT1SMN1; SMN2 | |
| SCHEMBL3057537 | 0.82 | DGAT1 (0.36) | DPP4DGAT1 | |
| SCHEMBL3049764 | 0.82 | GRM5 (0.37) | DPP4DGAT1MAPT | |
| SCHEMBL3037263 | 0.81 | DGAT1 (0.41) | DGAT1MAPT | |
| SCHEMBL3040687 | 0.81 | DGAT1 (0.35) | DPP4HTR2CDGAT1 | |
| SCHEMBL3047616 | 0.81 | DGAT1 (0.47) | DGAT1 | |
| SCHEMBL3053703 | 0.81 | DGAT1 (0.37) | DPP4DGAT1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2393811-A1 | 4-AMINO-7,8-DIHYDROPYRIDO[4,3-D]PYRIMIDIN-5(6H)-ONE DERIVATIVES | Pfizer Inc. (US) | 2011-12-14 | — | — | EP | claimed |
| WO-2010089686-A1 | 4-AMINO-7,8-DIHYDROPYRIDO[4,3-D]PYRIMIDIN-5(6H)-ONE DERIVATIVES | PFIZER INC. (US) | 2010-08-12 | — | — | WO | claimed |
| US-20100197591-A1 | 4-AMINO-7,8-DIHYDROPYRIDO[4,3-d]PYRIMIDIN-5(6H)-ONE DERIVATIVES | PFIZER INC | 2010-08-05 | — | — | US | claimed |
| EP-2393811-A1 | 4-AMINO-7,8-DIHYDROPYRIDO[4,3-D]PYRIMIDIN-5(6H)-ONE DERIVATIVES | Pfizer Inc. (US) | 2011-12-14 | — | — | EP | disclosed |
| WO-2010089686-A1 | 4-AMINO-7,8-DIHYDROPYRIDO[4,3-D]PYRIMIDIN-5(6H)-ONE DERIVATIVES | PFIZER INC. (US) | 2010-08-12 | — | — | WO | disclosed |
| WO-2010089686-A1 | 4-AMINO-7,8-DIHYDROPYRIDO[4,3-D]PYRIMIDIN-5(6H)-ONE DERIVATIVES | PFIZER INC. (US) | 2010-08-12 | — | — | WO | disclosed |
| US-20100197591-A1 | 4-AMINO-7,8-DIHYDROPYRIDO[4,3-d]PYRIMIDIN-5(6H)-ONE DERIVATIVES | PFIZER INC | 2010-08-05 | — | — | US | disclosed |
| US-20100197591-A1 | 4-AMINO-7,8-DIHYDROPYRIDO[4,3-d]PYRIMIDIN-5(6H)-ONE DERIVATIVES | PFIZER INC | 2010-08-05 | — | — | US | disclosed |
| US-20100197591-A1 | 4-AMINO-7,8-DIHYDROPYRIDO[4,3-d]PYRIMIDIN-5(6H)-ONE DERIVATIVES | PFIZER INC | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197591-A1 | 4-AMINO-7,8-DIHYDROPYRIDO[4,3-d]PYRIMIDIN-5(6H)-ONE DERIVATIVES | CDK7, DPYD, DHFR | DPP4 141/4885ABL1 13/4885SLC6A2 3116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.